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Summary In a variety of adult and childhood leukaemia cell samples collected at different states of the
disease, we analysed in a series of sequentially performed slot-blot or Northern-blot hybridisation experiments
the expression of genes possibly involved in multiple drug resistance (MDR) (mdrl/P-glycoprotein, DNA
topoisomerase II, glutathione-S-transferase x), and the expression of the DNA topoisomerase I and histone 3.1
genes. Occasionally, P-glycoprotein gene expression was additionally examined by indirect immunocyto-
fluorescence using the monoclonal antibody C219. No significant difference in mdrl/P-glycoprotein mRNA
levels between primary and relapsed state acute lymphocytic leukaemias (ALL) was seen on average. Second
or third relapses, however, showed a distinct tendency to an elevated expression of this multidrug transporter
gene (up to 10-fold) in part well beyond the value seen in the moderately cross-resistant T-lymphoblastoid
CCRF-CEM subline CCRF VCR 100. Increased mdrl/P-glycoprotein mRNA levels were also found in
relapsed state acute myelogeneous leukaemias (AML), and in chronic lymphocytic leukaemias (CLL) treated
with chlorambucil and/or prednisone for several years. Topoisomerase I and topoisomerase II mRNA levels
were found to be very variable. Whereas in all but one case of CLL topoisomerase II mRNA was not detected
by slot-blot hybridisations, strong topoisomerase I and topoisomerase II gene expression levels, frequently
exceeding the levels monitored in the CCRF-CEM cell line, were seen in many cell samples of acute leukaemia.
If topoisomerase II mRNA was undetectable, expression of topoisomerase I was clearly visible throughout.
These observations might be valuable considering the possible treatment with specific topoisomerase I or
topoisomerase II inhibitors. Significant positive correlations were found (i) for topoisomerase I and histone 3.1
gene expression levels in general (P<0.001), and (ii) in the CLL samples additionally for the expression levels
of the mdrl gene, and the histone 3.1, topoisomerase I, and glutathione-S-transferase ir genes, respectively.
Failure of chemotherapy during treatment of leukaemia is
supposedly caused by the resistance of the tumour cells to
antineoplastic drugs (Goldie & Coldman, 1984). Multidrug
resistant phenotypes of cultured cells selected in vitro have
been intensely studied in recent years. Two different
mechanisms confering resistance on these cells to a wide
variety of structurally unrelated cytotoxic agents have been
identified so far at the molecular level, (i) the enhanced
expression of the mdrl gene coding for an ATP-dependent,
transmembrane drug efflux pump called P-glycoprotein, and
(ii) an altered activity of the DNA topoisomerase II, a
nuclear enzyme possessing DNA double-strand passing acti-
vity by an ATP-dependent cleaving and rejoining process.
'Classical' multiple drug resistance (MDR) of cell lines
selected in vitro is basically mediated by the P-glycoprotein
(for review see Endicott & Ling, 1989). The so-called
'atypical' MDR (at-MDR) where the numerous topoisomer-
ase II inhibitors are affected could be associated with a
quantitatively or qualitatively altered activity of topoi-
somerase II (Pommier et al., 1986; Fernandes et al., 1990;
DeJong et al., 1990). Other investigations, however, point to
further as yet unrecognised mechanisms or a multifactorial
emergence of MDR of in vitro selected cell lines (McGrath &
Center, 1988; Deffie et al., 1988; Harker et al., 1989).
Clinical success of cancer therapy is strongly linked to the
type and status of the tumour. This is exemplified by haema-
tological malignancies. In general, childhood acute lympho-
blastic leukaemias (ALL) usually respond well to complex
protocols of intermittent chemotherapy applying combina-
tions of various antineoplastic drugs, whereas the prognosis
for adult ALL is worse. Showing lower curability than ALL
the childhood acute myelogeneous leukaemias (AML) are
still far better responding than adult AML. On the other
hand, chronic lymphocytic leukaemias (CLL) which are only
seen in adults usually receive either no chemotherapy at all,
or if the disease is in progress, a combination of an
alkylating agent and prednisone. A cure of CLL is usually
not possible. In the case of the most prevalent childhood
leukaemia, the acute lymphoblastic leukaemia, currently only
about 20% relapse. Without bone marrow transplantation,
the prognosis of relapsed leukaemia at present is bad, which
actually might be due to the emergence of tumour cells less
sensitive to antineoplastic agents. The molecular mechanisms
of this clinically observed refractoriness of tumours to
chemotherapy are still little understood. Several observations,
however, point to the involvement of the P-glycoprotein, as
(i) the unresponsiveness of tumours derived from tissues with
an intrinsically high P-glycoprotein expression (Fojo et al.,
1987), (ii) the emergence of P-glycoprotein expression in
specimens of relapsed state malignancies after chemotherapy
(Ma et al., 1987; Goldstein et al., 1989; Volm et al., 1989;
Musto et al., 1990; Pirker et al., 1991), and (iii) reports on
the successful treatment of drug-resistant tumours by includ-
ing the calcium channel blocker and P-glycoprotein binding
drug verapamil in chemotherapy protocols (Dalton et al.,
1989). However, other studies do not support the view of a
frequently occurring link between elevated P-glycoprotein
levels and therapy failures of leukaemias (Ito et al., 1989;
Ubezio et al., 1989). Moreover, many clinically used anti-
neoplastic drugs like ara C, cisplatin, or most alkylating
agents do not even belong to the group of agents involved in
the MDR-phenotype of cells selected in vitro. Hence, differ-
ent mechanisms conferring drug resistance on tumour cells in
vivo have to be considered.
Many antineoplastic drugs used clinically are inhibitors of
the topoisomerase II and substrates for the P-glycoprotein
mediated efflux as well, for instance, anthracyclines like
adriamycin, or epipodophyllotoxins like teniposide. It has
been suggested that the clinical response to epipodophyllo-
toxins could be dependent on a cell's topoisomerase II level.
These drugs apparently stabilise an intermediate in the topo-
isomerase II catalysed reaction with the consequence of DNA
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damage which might be lethal to the cell. Thus, reduced
levels of the topoisomerase II could confer resistance to
drugs targeted at the topoisomerase II by giving better
chances to the cell's DNA repair systems (Holden et al.,
1990). On the other hand, high topoisomerase II levels vice
versa might be indicative for a good response of tumours to
these kinds of drugs (Sullivan et al., 1987; Davies et al.,
1988). Topoisomerase I is another nuclear enzyme involved
in the regulation of DNA topology by relaxation of super-
coils in an ATP-independent process (Liu, 1989). Campto-
thecins are specific inhibitors of topoisomerase I which are
currently under investigation for use as antineoplastic drugs
(Giovanella et al., 1989), and appear not to be affected in
multidrug resistance (Chen et al., 1991).
The activity of the glutathione-S-transferase x was dis-
cussed as a further mechanism contributing to the MDR
phenotype (Batist et al., 1986). It might, however, rather be
involved in resistance of tumour cells to alkylating agents or
oxidative stress (Fairchild et al., 1990; Waxman, 1990). The
expression of the cell cycle regulated histone 3.1 gene repre-
sents an indicator of DNA synthesis activity (Stein et al.,
1984; Venturelli et al., 1988) which is an important para-
meter, because DNA replication is one of the main targets of
antineoplastic drugs.
Considering the possible complex genesis of a clinically
observed refractoriness of tumours to treatment we analysed
the expression of the mdrl/P-glycoprotein gene together with
the variety of other genes in different types of leukaemias, at
several times during progression of the disease. This might be
helpful for the evaluation of drug resistance or an enhanced
vulnerability of leukaemic cells to certain antineoplastic
agents.
Materials and methods
Materials
Blotting membranes (Hybond N+, Hybond N), labelling kits
(Multiprime DNA Labelling System), [x-32P]dCTP (specific
activity > 3000 Ci mmol 1; 1 Ci = 37 GBq) were obtained
from Amersham (Braunschweig/Germany). All other chemi-
cals, supplies and tissue culture media were of the purest
grade and were purchased from commercial sources.
Cell lines andleukaemia cells samples
The human T-lymphoblastoid cell line CCRF-CEM was
obtained from the American Type Culture Collection, Rock-
ville, MD/USA (ATCC CCL 119). The selection of multi-
drug-resistant CCRF-CEM sublines was published elsewhere
(Gekeler et al., 1988; Niethammer et al., 1989). The cell lines
used in this work were designated CCRF VCR 100, CCRF
VCR 1000, and CCRF ACTD 400 according to the final
vincristine or actinomycin D concentration (in ng ml-'),
respectively, used for selection and maintenance. A 'rever-
tant' subline designated CCRF ACTD (REV) was main-
tained for more than a year without the drug. It showed a
substantial decrease, though not a complete loss of resistance
(Kimmig et al., 1990). Peripheral blood specimens or bone
marrow aspirates were collected from normal donors and
patients suffering from leukaemia in heparin without stabili-
ser. The mononuclear cells were concentrated by a standard
Ficoll-Hypaque technique (Lymphoprep, Nycomed, Oslo/
Norway), washed twice, frozen in the presence of 7% DMSO
under controlled conditions, and stored in liquid nitrogen
until used for analysis.
RNA isolation and analysis
Total cellular RNA was extracted from the cell samples by
lysis in guanidine thiocyanate, followed by centrifugation
through cesium chloride (Chirgwin et al., 1979). The concen-
tration of RNA in each sample was determined spectro-
photometrically. Routinely, the quality of each RNA sample
was monitored by ethidium bromide staining after electro-
phoresis in a 1% agarose/6% formaldehyde gel. For slot-blot
hybridisations, 2.5 jg of each RNA sample were fixed onto
Hybond N+ membranes using the Minifold II slot blotting
apparatus (Schleicher & Schiill, Dassel/Germany). For
Northern-blot hybridisations 5 glg of total cellular RNA were
electrophoresed in a 1% agarose/6% formaldehyde gel, and
transferred by electroblotting onto Hybond N+ membranes
as recommended by the supplier (Amersham, Braunschweig/
Germany). The RNA was fixed by UV-irradiation of the wet
membranes using the Stratalinker 1800 (Stratagene, La Jolla/
USA) as recommended by the supplier. Additionally, the
membranes were baked thereafter at 80°C for 2 h. Thus, no
significant loss of signal intensities were found after reprob-
ing the filters up to six times.
As hybridisation probes we used the gel purified inserts of
(i) the plasmid pcDR containing a 699 bp EcoRI cDNA
fragment starting from position 1177 of the human P-glyco-
protein mdrl gene (Chen et al., 1986), (ii) the plasmid
p3.2.4(M) containing a 2.2 kb cDNA EcoRI fragment of the
human topoisomerase I gene (Romig & Richter, 1990), (iii)
the plasmid phTOP2-1 containing a 2.4 kb cDNA EcoRI
fragment of the human topoisomerase II gene (Tsai-Pflug-
felder et al., 1988), (iv) the plasmid pLK288 containing a
1.7 kb EcoRI fragment of the human histone 3.1 gene, (v)
the plasmid pGPi2 containing a 708 bp EcoRI cDNA frag-
ment of the human glutathione-S-transferase class it gene
(Kano et al., 1987), and (vi) the plasmid pHF3-Al containing
a 2 kb BamHI fragment of the human ,-actin cDNA (Gunn-
ing et al., 1983). The probes were labelled with [32P]dCTP to
a specific activity of 1-2 x 109 d.p.m. pgg' by 'oligolabelling'
(Feinberg & Vogelstein, 1983), and used at a concentration
of 1-2 x 106 d.p.m. ml-'. The hybridisation procedure was
performed as communicated earlier (Gekeler et al., 1988),
besides 5% instead of 7% SDS (SDS = sodium dodecyl sul-
fate) were used. The filters were washed to a final stringency
of 0.1 x SSC/0.1% SDS at 65°C (SSC = 0.15 M sodium
chloride, 0.015 M sodium citrate), and autoradiographed
with Hyperfilm MP (Amersham, Braunschweig/Germany) at
- 80°C. For the quantitative evaluation of the autoradio-
graphs by a Ultroscan XL 2222-20 laserdensitometer
(Pharmacia-LKB, Freiburg/Germany) the films were exposed
without intensifying screens. As size markers we used RNA-
ladders purchased from Boehringer Mannheim/Germany or
Gibco-BRL, Freiburg/Germany.
In pilot slot-blot hybridisation experiments we tested the
performance of the mdrl signal intensities using Hybond N
or Hybond N+ membranes (Amersham), respectively, in cor-
relation to the amount of mdrl mRNA in the sample. There-
fore, 100 ng to 15 jig of total RNA obtained from the multi-
drug-resistant CCRF-CEM subline CCRF ACTD 400 were
fixed onto the membranes as described. In the lower range
(100 ng to 2.5pg) Escherichia coli rRNA (Boehringer Mann-
heim) was added up to a final amount of 2.5tLg. Using the
Hybond N+ membrane stronger signal intensities together
with a better approximation to a linear relationship between
the amount of mRNA loaded and the signal intensity were
obtained (data not shown).
Indirect immunocytofluorescence
Cell suspensions of the CCRF-CEM cell lines or mono-
nuclear cell fractions of the leukaemias were washed twice in
ice-cold 0.9% sodium chloride, spotted onto gelatine coated
slides and fixed in -20°C cold acetone (fluorescence free,
Merck, Darmstadt/Germany) and stored at - 80°C. Accord-
ing to Volm et al. (1989) we used the streptavidin-biotin-
phycoerythrin method (Amersham). The fixed cells were
incubated for 2 h with the monoclonal P-glycoprotein-specific
antibody C219 at a concentration of 10 tgml-' (Isotopen
Diagnostik CIS, Dreieich/Germany). After washing, the cells
were incubated with biotinylated sheep-anti-mouse second
antibody, and then with the streptavidin-biotinylated-R-
phycoerythrin-complex (Amersham). After addition of a
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phycoerythrin-fluorescence, the slides were dried and cover-
slipped. For control, aliquots of the same cell samples were
stained using mouse isotype IgG2a (Coulter Electronics,
Krefeld/Germany) instead of the P-glycoprotein-specific anti-
body C219. Total cells were visualised by phase contrast
microscopy.
Statistical analysis
The statistical evaluations were made by student's t-test.
Evaluation of the relationship between the expression values
of two genes was done applying Spearman's rank order
correlation test.
Results
In series of sequentially performed slot-blot hybridisation
experiments the RNA samples prepared from cell lines, heal-
thy donors or leukaemia cell samples were evaluated for gene
expression using the mdrl/P-glycoprotein, topoisomerase I,
topoisomerase II, histon 3.1, glutathione-S-transferase class,
or P-actin specific gene probes. To control the amount of the
RNA samples fixed on the membranes we routinely used the
A(9'
c,c '
mdr 1
topo I
topo 11
his3.1
1-actin
hybridisation signal obtained with the P-actin gene probe.
This appeared justified according to Venturelli et al. (1988).
The hybridisation signal intensities of the samples were com-
pared to the signal intensities obtained with RNA of the
multidrug-resistant subline CCRF VCR 100 which were arbi-
trarily set 100.
A fraction of typical slot-blot hybridisation experiments is
shown in Figure la and b. The signals seen after sequentially
hybridising one and the same membrane with the various
gene probes are presented. Part of the RNA samples were
additionally analysed by Northern-blot hybridisations as
exemplified in Figure 2. Gene expression levels monitored by
either method corresponded quite well. So, slot-blot hybri-
disation was the method of choice for the repeated evalua-
tion of the numerous samples. The results are summarised in
the Tables I-IV. The values listed are usually means
obtained in several independently performed experiments.
Excepting signal intensities scoring below about 50 arbitrary
units, standard deviations were usually less than 20%. The
significance of differences will be notified, if it appears impor-
tant.
The gene expression levels found in the T-lymphoblastoid
cell lines and PBMC collected from healthy donors are listed
in Table I. The moderately multidrug-resistant sublines
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Figue 1 a, Sequentially performed slot-blot hybridisations of
one and the same membrane loaded with RNA prepared from
the T-lymphoblastoid cell line CCRF-CEM, multidrug-resistant
CCRF sublines, healthy donors, and various cell samples from
leukaemias (see Tables) using mdrl/P-glycoprotein, topoisomerase
I, topoisomerase II, histone 3.1, and f-actin specific probes of the
human genes as described above. b, Sequentially performed slot-
blot hybridisations using mdrl/P-glycoprotein, glutathione-S-
transferase it and $-actin specific probes.
Figure 2 Sequentially performed Northern-blot hybridisations of
RNA prepared from various cell samples from leukaemias (see
Tables) using topoisomerase II, topoisomerase I, P-actin, and
histone 3.1 specific gene probes.
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Table I Gene expression in multidrug-resistant CCRF-CEM sublines, and
peripheral blood mononuclear cells (PBMC) from healthy donors
Cell sample mdrl/P-gp Topo II Topo I His 3.1 Gst-ir
CCRF-CEM 21/ICF: (-) 299 127 111 98
CCRF VCR 100 100/ICF: + 100 100 100 100
CCRF ACTD (REV) 159/ICF: + 202 98 109 150
Donor A
Donor B
Donor C
21/ICF: (+) (-) 117
25/ICF: (+) (-) 85
28/ICF: (+) (-) 98
30 na
25 35
65 38
Mdrl/P-glycoprotein (P-gp), topoisomerase (Topo), histone 3.1 (His 3.1), and
glutathione-S-transferase c (Gst-it) mRNA levels were estimated as described
above.
The signal intensities obtained with material ofthe multidrug-resistant cell line
CCRF VCR 100 were arbitrarily set 100. The values listed are usually means
originating from up to seven independent experiments.
P-glycoprotein expression was additionally examined by indirect
immunocytofluorescence (ICF) using the monoclonal antibody C219. Ifno other
data arepresented, RNApreparation was notpossible. The signal intensities were
scaled as follows: (-), no stained cell or hybridisation signal visible; (+), weak or
moderately, but heterogeneously stained (<25% ofthe cells scored positive); +,
weakly, but homogeneously stained, + +, moderately or strongly, rather
homogeneously stained. na, not assayed.
Table II Gene expression in acute lymphoblastic leukaemias (ALL)
Age Blasts
Patient (years) (%) Diagnosis/Status mdrl/P-gp Topo II Topo I His 3.1 Gst-i
(adult ALL)
ALL 1 (SK)
ALL 2 (BU)
ALL 3 (TO)
22
25
21
ALL 4-1 (DB) (bm) 34
ALL 4-2a (bm) 34.2
ALL 4-2b 34.2
ALL 4-3 34.4
90 cALL, 2nd relapse after BMT 21
80 B-ALL, 1st relapse 26
80 cALL, primery leukaemia 44/ICF: (-)
80 cALL; 1st relapse
2 remission
none
35 2nd relapse
31
102
58
42
362 144 124
94 206 154
98 244 293
109 121 24
258 363 197
(-) 190 18
137 108 na
(childhood ALL)
ALL 5 (EW) 6.9 90 cALL, primary leukaemia 144 na na na
ALL 6 (AS) 10.7 70 cALL, primary leukaemia 88 na 734 na
ALL 7 (MKA) 6.1 100 cALL, primary leukaemia 119 201 361 172
ALL 8-1 (JB) (bm) 12.3 100 cALL, 1st relapse after 3 years 89/ICF: + 260 182 90
(prior to treatment)
ALL 8-2 12.4 40 2nd relapse ICF: (+)
ALL 9-1 (RK) 12.9 84 cALL, 1st relapse 63 72 244 203
ALL 9-2 13.2 98 2nd relapse ICF: +
ALL 10 (CST) 8.6 90 cALL, 1st relapse 67/ICF: + 252 103 73
ALL 11 (DP) 0.7 94 cALL, 1st relapse 102/ICF: + 62 118 101
ALL 12 (UK) 17.7 93 cALL, 1st relapse after 5 years 342/1CF: + + 28 na na
ALL 13 (MF) 12.1 92 cALL, 1st relapse 90/ICF: + 150 226 157
ALL 14 (SO) 5.3 20 cALL, 1st relapse 61/ICF: (+) 200 262 156
ALL 15-1 (SK)
ALL 15-2
ALL 16-1 (MS)
ALL 16-2
ALL 17-1 (DL)
ALL 17-2
ALL 17-3
ALL 17-4
ALL 18-1 (CS)
ALL 18-2
ALL 19-la (AD)
ALL 19-lb (bm)
ALL 19-2 (bm)
ALL 20-1 (AZ)
ALL 20-2
ALL 20-3
ALL 21-1 (SH)
ALL 21-2 (bm)
ALL 21-3
ALL 22 (AG)
8.8 88 cALL, 1st relapse
10.1 96 2nd relapse
11.3 98 cALL, 1st relapse
12.3 98 2nd relapse after ABMT
14.1
15.3
15.8
16.1
99 Ph+, 1st relapse
94 2nd relapse
55 3rd relapse
70 4th relapse
11.4 96 cALL, 1st relapse
11.7 90 2nd relapse
5.7
5.7
6.3
7.3
8.5
9.3
6.1
7.1
8.2
73 T-ALL, primary leukaemia
96
95 1st relapse
93 cALL, primary leukaemia
93 1st relapse
85 2nd relapse after ABMT
80 cALL, primary leukaemia
90 1st relapse
100 isolated pleura relapse
9.3 95 cALL, 3rd relapse
64
101
na na na
98 149 142
19 na 127 na
79 293 227 na
20 na 511 na
262/ICF: + 158 742 73
81/ICF: (+) 71 190 na
ICF: +
27 125 449 209
87/ICF: + 75 223 120
45/ICF: (-) 74 162 39
269 200 305
184 323 190 141
141
102 144 282 51
ICF: (+)
ICF: (+)
45 100 64 35
43/ICF: (-) 349 126 na
na/ICF: + 65 na na
ICF: + +
90
90
na
61
43
na
41
59
32
46
79
na
46
53
na
82
31
32
56
194
266
32
na
45
na
na
na
168
95
34
48
61
na
See Table I footnotes.
In the relapsed state the leukaemias usually were treated according to an ALL protocol which includes prednisone, vincristine,
daunomycin, etoposide, methotrexate, ara C, cyclophosphamide, and asparaginase; bm = bone marrow mononuclear cells; BMT,
ABMT = (autologous) bone marrow transplanation; Ph+ = Philadelphia chromosome positive.512 V. GEKELER et al.
Table III Gene expression in peripheral blood mononuclear cells (PBMC) from chronic lymphocytic leukaemias (CLL)
Age Leukocytes Lymphocytes
Patient (years) (109/lt') (%) Chemotherapy mdrl/P-gp Topo II Topo I His 3.1 Gst-c
CLL 1 (AK) 58 29.6 88 none 70 na 38 na 69
CLL 2 (LM) 75 166.0 97 none 102 (-) 190 124 42
CLL 3 (EJ) 68 140.0 88 none 77 (-) 58 121 59
CLL 4 (MW) 57 233.2 99 none 131 (-) 157 246 753
CLL5(KB) 62 21.0 81 none 86 (-) 99 91 182
CLL 6 (AF) 82 45.5 81 none 68 (-) 54 33 209
CLL 7 (MM) 68 136.3 96 none 97 (-) 150 59 185
CLL 8 (KU) 74 20.7 89 none 68 (-) 127 74 141
CLL 9 (HG) 53 28.6 85 Chlorambucil (9 years) 100 (-) 77 na 72
CLL 10 (FW) 63 48.4 97 Chlorambucil, PRED 80 na na na 81
CLL 11 (NS) 76 21.4 82 Chlorambucil, PRED 49 (-) na 113 32
CLL 12 (KHR) 59 17.2 92 Chlorambucil, PRED 189 (-) 114 405 321
CLL 13 (FG) 67 120.0 100 Chlorambucil, PRED 119/ICF: (+) (-) 186 144 na
CLL 14 (WL) 63 12.9 99 Chlorambucil, PRED 149 (-) 155 167 192
CLL 15 (AM) 67 35.7 91 PRED 74 (-) 180 57 148
CLL 16 (FS) 66 29.8 38 Chlorambucil, PRED 180 (-) 236 238 122
CLL 17-1 (HS) 57 85.0 97 Chlorambucil, PRED 68 (-) 55 na na
CLL 17-2 57.2 27.3 90 PRED 176 (-) 187 292 235
CLL 17-3 57.4 31.0 91 PRED 83 (-) 80 na 204
CLL 17-4 58 85.7 97 PRED 425 67 157 448 128
CLL 18-1 (IG) 51 187.0 91 Chlorambucil, PRED 66 (-) 98 100 123
CLL 18-2 51.2 138.0 97 Chlorambucil, PRED 46 (-) 96 60 101
CLL 18-3 52.2 35.0 75 Chlorambucil, PRED 126/ICF: (+) (-) 62 320 na
CLL 18-4 52.7 30.2 84 Chlorambucil, PRED 442 (-) 239 492 560
See Table I footnotes.
Table IV Gene expression in acute myelogeneous leukaemias (AML)
Age Blasts
Patient (years) (%) Diagnosis/Status mdrl/P-gp Topo II Topo I His 3.1 Gst-i
AML I (FM) (bm) 57 80 Primary leukaemia 43 98 461 39 na
AML 2(ES) 51 90 Relapse 151 (-) 102 28 74
AML 3 (JS) 19.5 66 Relapse 476 355 na na 59
AML 4 (YD) 19 80 Relapse after BMT 54 71 113 na 31
AML 5 (PR) 15.3 96 Primary leukaemia 9 20 129 43 54
AML 6 (AB) 11.7 77 Primary leukaemia 59 90 162 na 59
AML 7-1 (CD) 11.3 93 Primary leukaemia 22/ICF: (-) 58 71 36 67
AML 7-2 11.8 100 Relapse after ABMT 78/ICF: + + 62 124 na 62
See Table I footnotes. In the relapsed state AML usually were treated according to the AML protocol which includes ara C,
daunomycin, and etoposide.
CCRF VCR 100 and CCRF ACTD (REV) show 'relative
resistances' to actinomycin D of 10-fold and 12-fold, to
vincrinstine of 257-fold and 107-fold, and to adriamycin of
24-fold and 42-fold, respectively, measured by a 72 h growth
assay (Kimmig et al., 1990).
Acute lymphoblastic leukaemias
We examined four adult and 18 childhood ALL in primary
and relapsed states (Table II). With a few exceptions the
specimens consisted of > 80% leukaemic blast cells. The
leukaemias usually were treated by various ALL protocols
for primary and relapsed states, respectively, including pred-
nisone, vincristine, adriamycin, daumomycin, methotrexate,
cisplatin, asparaginase, ara C, and cyclophosphamide. A
rather low mdrl gene expression was seen in adult ALL.
Thus, in specimens originating from three relapsed state
leukaemias poorly responding to chemotherapeutic treatment
the expression levels were hardly significant at all (ALL 1,
ALL 2, and the bone marrow sample ALL 4-1). However, a
sample of the ALL 4 at a later presentation in remission after
chemotherapy showed distinct mdrl expression in the bone
marrow aspirate, although only 2% blast cells were counted.
The patients terminally relapsed, but mdrl expression
remained low. At the same time, a drastic increase in the
topoisomerase II mRNA level could be monitored in the
PBMC fraction.
Examination of childhood ALL revealed no significant
differences in gene expression levels on the average, if the
relapsed state leukaemias (18 specimens) were compared to
the untreated primary leukaemias (six specimens). All
primary leukaemias showed distinct mdrl/P-glycoprotein
gene expression, in part even above the value seen in the cell
line CCRF VCR 100. Nonetheless, very high values were
monitored in two relapsed state leukaemias (ALL 12 and
ALL 17-2). It might be worth noting that bone marrow cell
samples showed 2- or 3-fold higher mdrl mRNA levels (ALL
4-2 and ALL 19-1) than the corresponding PBMC fractions
collected at the same time. Three relapsed state leukaemias
(ALL 16-1, ALL 17-2, ALL 18-1) showed no significant
expression of the mdrl gene (below 30 arbitrary units; CCRF
VCR 100 = 100) in PBMC samples (96-99% blast cells).
However, mdrl mRNA levels were distinctly, in some cases
drastically, elevated throughout, if second or third relapses
were examined (ALL 15-2, ALL 16-2, ALL 17-2,3, ALL
18-2). The increases were all statistically significant. As an
example, the values are detailed for the sample ALL 16-1
(19 i 15 arbitrary units; n = 2), and the sample ALL 16-2
(79 ± 11 arbitrary units; n = 7). This difference is statistically
significant at the P<0.001 level.
Topoisomerase II gene expression was quite variable, but
usually rather strong especially in some relapsed state ALL,
i.e. comparable to the level found in the T-lymphoblastoid
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cerning topoisomerase I gene expression in ALL. Thus, a
correlation of a low topoisomerase II gene expression with
the unresponsiveness of the blast cells to chemotherapy, as
suggested to be a mechanism of a topoisomerase II
associated multiple drug resistance of cell lines selected in
vitro, was not seen in general. An exception is represented by
the ALL 12 where, compared to CCRF-CEM cells, about
10-fold lower topoisomerase II mRNA levels were monitored
together with a very high mdrl/P-glycoprotein gene expres-
sion.
A significant correlation was solely found for topoiso-
merase I and histone 3.1 mRNA levels (r, = 0.5156, n = 21,
P<0.01). Histone 3.1 expression most likely corresponds to
DNA synthesis and the proliferation status of the tumour
cells (Venturelli et al., 1988). Though constitutively expressed
in nucleated cells, the topoisomerase I gene is highly regu-
lated responding to a variety of stimulations (Romig & Rich-
ter, 1990). Glutathione-S-transferase x gene expression, with
two exceptions (relapsed state ALL 16, and the bone marrow
sample of the primary ALL 19-lb), were moderate, if com-
pared, however, to the fairly distinct expression found in
CCRF-CEM cell lines.
Chronic lymphocytic leukaemias
Eighteen CLL samples, all representing a B-cell CLL, were
examined, eight of which had not received any chemotherapy
(Table III). The drugs applicated for the treatment of CLL,
the alkylating agent chlorambucil and the corticosteroid pred-
nisone, are not usually affected in multidrug-resistant
phenotypes of cell lines selected in vitro. However, two
leukaemias (CLL 17 and CLL 18) examined several times
during chemotherapy showed quite strong relative increases
of mdrl expression levels in the most recent cell samples. On
average, however, no statistically significant difference was
revealed, if the data from untreated and treated leukaemias
were compared altogether.
Except the sample CLL 17-4, in all CLL specimens examin-
ed topoisomerase II mRNA could not be detected by slot-blot
hybridisation experiments, whereas distinct topoisomerase I
expression was identified throughout. Surprisingly, several
significant positive correlations of gene expression levels were
found, i.e. highly significant for the mdrl and histone 3.1
mRNA levels (r, = 0.8526, n = 19, P<0.001), the mdrl and
topoisomerase I mRNA levels (r, = 0.6076, n = 22, P <
0.005), and mdrl and glutathione-S-transferase x mRNA
levels (r, = 0.5415, n = 23, P<0.005), and, as in the ALL
samples, for topoisomerase I and histone 3.1 mRNA levels
(r, = 0.4303, P<0.05). It appears interesting to note, how-
ever, that the significance of correlations turned out to be
somewhat different, if untreated or treated CLL were
examined separately. Thus, in untreated CLL (n = 8) no
correlation at all was seen for mdrl and glutathione-S-
transferase x mRNA levels, in the chemotherapeutically
treated CLL this correlation was significant at the P< 0.025
level (r. = 0.6264, n = 13). For the mdrl and histone 3.1
mRNA levels the correlation was hardly significant (rs=
0.6786, n = 7, P = 0.05) in case of the untreated leukaemias,
whereas in the treated CLL the positive correlation was
highly significant (r, = 0.9021, n = 12, P<0.001).
Acute myelogeneous leukaemias
Four adult and three childhood AML were examined (Table
IV). In all relapsed state AML mdrl mRNA levels were
significant (AML 4, AML 7-2) or high (AML 2, AML 3).
The patient JS (AML 3) early relapsed after intense chemo-
therapy. Then, virtually no response of his blast cell popula-
tion to various combinations of drugs was seen. A strong
topoisomerase II gene expression was revealed in this case.
The bone marrow mononuclear cells of AML 1, a primary
leukaemia, showed very high topoisomerase I expression (see
also the Northern-blot hybridisation, Figure 2). Remarkably,
in the sample of the relapsed state AML 2 (90% blast cells)
no topoisomerase II mRNA was detected (Table IV, Figure
2), whereas the topoisomerase I mRNA level was comparable
to the values seen in the CCRF-CEM cell lines. Thus, the
AML-2 represents another relapsed state acute leukaemia
(see also ALL 12) where the drug resistance might possibly
be caused by two rather independent mechanisms, i.e. an
increased mdrl/P-glycoprotein, and a distinctly lowered
topoisomerase II gene expression. Glutathione-S-transferase
I mRNA levels did not show peculiarities.
Indirect immunocytofluorescence
Part of the cell samples was analysed by indirect immuno-
fluorescence using the P-glycoprotein specific monoclonal
antibody C219. Multidrug-resistant sublines of the T-
lymphoblastoid cell line CCRF-CEM were taken as a refer-
ence for P-glycoprotein expression.
The results are listed in the corresponding tables; some
examples are shown in Figure 3. All cell samples were stained
and photographed in the same manner. Figure 3a represents
the moderate multidrug-resistant subline CCRF VCR 100
which was used as a standard for the evaluation of mRNA
levels as detailed above. The limit of sensitivity of this
immunofluorescence approach for detecting P-glycoprotein
expressing cells seems hereby about to be represented. This is
important to note, because the P-glycoprotein expression
level in CCRF VCR 100 cells might already be well beyond
the value where the resistance of tumour cells to chemo-
therapy may become a clinical problem. For comparison,
stained samples of the highly cross-resistant subline CCRF
ACTD 400 (Kimmig et al., 1990) with relative resistances of
571-fold to actinomycin D, 71-fold to adriamycin, or 2831-
fold to vincristine (Figure 3b), and the subline CCRF VCR
1000 (Kimmig et al., 1990) with relative resistances of 102-
fold to actinomycin D, 90-fold to adriamycin, or 1760-fold to
vincristine (Figure 3d), are shown as well. In Figure 3c the
staining of a cell sample originating from a Russian child
suffering from acute lymphoblastic leukaemia is presented.
The patient received a continuous chemotherapy at home
including methotrexate, prednisone, ara C, cyclophosphamide
and various anthracyclines, and arrived in Tubingen in bad
condition. The leukaemic blast cell population did not res-
pond any more to chemotherapy, and the child died soon
thereafter. Because of the small sample size the preparation
of RNA was not possible at this time. However, the
immunofluorescent staining of this cell sample revealed a
rather homogenous and intense P-glycoprotein expression in
nearly every cell examined. Figure 3e shows a sample of the
relapsed state leukaemia ALL 20-2 (AZ) (93% blasts, see
also Table II) from which only a minute sample was avail-
able as well. Clearly, P-glycoprotein positive cells were seen.
Patient SH came up with an isolated pleura relapse. ICF
analysis revealed a distinct staining of the cells (ALL 21-3).
Cells collected from the first relapse (ALL 21-2) were 'P-
glycoprotein negative' by ICF.
The data obtained by slot-blot hybridisations using RNA
of the AML 7 samples (Table IV) were checked by ICF. No
significant immunostaining was detected in case of the
primary leukaemia (AML 7-1). In the relapsed state after
autologous bone marrow transplantation (AML 7-2, 100%
blasts), however, the immunostaining of the sample appeared
to be inhomogeneous, but about 50% of the cells showed
very strong signal intensities (Figure 3f). While a clear eleva-
tion of the mdrl mRNA level was also found here after
slot-blot hybridisations, the increase monitored hereby
appeared to be less dramatic. This might at least partly be
due to the fact that the latter method detects the average
expression level in the whole blast cell population.
Cell samples of the parental, sensitive cell line CCRF-CEM
did not show a significant P-glycoprotein specific immuno-
fluorescence using our batches of the C219 antibody. In
contrast, PBMC fractions of healthy donors showed some
immunostaining which appeared to be quite heterogeneous,
however, presumably representing the P-glycoprotein
expression in specialized subpopulations of haematopoietic
cells like macrophages, for example (Schlaifer et al., 1990).514 V. GEKELER et al.
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Figure 3 Indirect immunocytofluorescence using the monoclonal antibody C219: cell samples from the multidrug-resistant sublines
a, CCRF VCR 100; b, CCRF ACTD 400; d, CCRF VCR 1000, and the leukaemias c, ALL 22 (AG); e, ALL 20-2 (AZ); f, AML
7-2 (CD).
Discussion
Gene expression was determined by us mostly at the mRNA
level in slot-blot and Northern-blot hybridisation experi-
ments. In a fraction of the samples, P-glycoprotein gene
expression was analysed by indirect immunocytofluoresence
(ICF) using the monoclonal antibody C219. As the leukaemic
cell samples frequently represent more or less heterogeneous
cell populations, the analysis of P-glycoprotein expression by
an immunocytofluorescence technique appeared to be useful.
Even a single drug-resistant tumour cell might pose serious
problems in curing the disease. Moreover, an occasional
comparison of the data obtained with the two different
methodical approaches at the mRNA or protein level, respec-
tively, seemed to be important. In some cases, however,
RNA preparation was not possible at all, because of the
small sample size.
The monoclonal antibody C219 was used for examination
of leukaemia cell samples by others as well (Ma et al., 1987;
Volm et al., 1989; Musto et al., 1990; Schlaifer et al., 1990).
Some limitations using this reagent have to be considered,
though. This antibody apparently cross-reacts with the mdr3
gene product the involvement of which in drug resistance is
still unclear (Schinkel et al., 1991). Leukaemias of the B-cell
lineage were reported to express the mdr3 gene at significant
levels (Herweijer et al., 1990). Nevertheless, we mostly
examined mdrl gene expression at the mRNA level in
parallel using a gene probe which was not suspected to
cross-react with the mdr3 gene under the highly stringent
hybridisation conditions applied in this work according to
Southern-blot hybridisation experiments performed with
human genomic DNA (data not shown). This takes also
account for another problem which might arise by using the
C219 antibody, i.e. its cross-reaction to blood group A
carbohydrate determinants due to contaminating antibodies
in some commercial C219 lots recommending a reevaluation
of P-glycoprotein expression data concerning samples of
endothelial cells or epithelial tissues which are known to
carry blood group antigens (Finstad et al., 1991). However,
this appeared not to be a source of error in our work,
because we found no link between the immunostaining-intens-
ities of the samples, comprising mononuclear cell fractions
consistently, and the blood group of the individuals. There-
fore, it appears justified to state that in consideration of the
peculiarities of the principally different approaches applied
for detecting mdrl/P-glycoprotein gene expression the results
were nonetheless similar.
In agreement with the reports from others, a substantial
part of the relapsed state acute lymphatic leukaemias examin-
ed in this work (the adult relapsed state ALL 1, ALL 2, and
ALL 4-1, the childhood relapsed state ALL 16-1, ALL 17-1,
ALL 18-1, ALL 21-2) did not show a significant mdrl gene
expression at the mRNA level. A follow-up, however, reveal-
ed a clear increase of mdrl/P-glycoprotein mRNA levels in
most of the second or third relapses of childhood ALL (ALL
15, ALL 16, ALL 17, ALL 18) indicating that P-glycoprotein
expressing and supposedly resistant blasts cells were selected
in vivo by prolonged treatment of the disease. A distinct
elevation of mdrl/P-glycoprotein mRNA levels was also seen
in the few relapsed states of adult or childhood AML
analysed by us. The highly significant elevation of mdrl gene
expression after a prolonged treatment with chlorambucil
and prednisone in two chronic lymphocytic leukaemias (CLL
17, CLL 18) is in accordance with the work of Holmes et al.
(1990a) where a transient increase of mdrl expression under
chemotherapy with chlorambucil or cyclophosphamide was
demonstrated. However, the authors suggest that mdrl
expression might be rather linked to as yet unknown factors
in the development of CLL because increases of mdrl mRNA
levels were found in untreated CLL as well, which is consis-
tent with the data presented in this work (Table III).
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unclear in leukaemias like CLL treated with drugs (chloram-
bucil, prednisone) usually not associated with the MDR-
phenotype of in vitro selected multidrug-resistant cell lines,
the expression level of the multidrug transporter might be
crucial for the success of the complex, empirically developed
protocols for the chemotherapeutic treatment of other types
of leukaemias, even if not the whole variety of the drugs
applicated is affected in the same manner. Furthermore, it is
not known at the present time which the brink might be for
therapy success or failure in terms of the mdrl/P-glycoprotein
expression level. No cell sample virtually 'mdrl/P-
glycoprotein negative' was seen by us applying slot-blot hyb-
ridisations. Even the parental T-lymphoblastoid cell line
CCRF-CEM showed low mdrl mRNA levels (21 ± 11 arbit-
rary units, n = 7; Table I) which was proved not to represent
unspecific background by a polymerase-chain-reaction (PCR)
approach (Gekeler et al., 1990; Noonan et al., 1990). The
child C.E.M. from which this cell line was derived, was
intensely drug treated without response according to Foley et
al. (1965). Thus, the specimens examined by us mostly
originate from rather problematic leukaemias. Only three of
the acute leukaemias examined in this work (ALL 5, ALL 7,
ALL 13) are in remission at present, all of which showed
distinct expression of the drug transporter gene, however
(Table II). Recently, a coincidence of the absence of mdrl
gene expresssion determined by PCR in untreated nonlym-
phocytic leukaemias and the remission frequency observed
for this type of leukaemia was found (Noonan et al., 1990).
These studies suggest that the success of chemotherapy in
certain leukaemias is associated with the complete silence of
the mdrl/P-glycoprotein gene in the tumour cells, and if mdrl
expression, whether low or high, is seen at all by any of the
methods described so far, the prognosis might be bad in
general. Sooner or later chemotherapy would then select for
mdrl/P-glyprotein expressing tumour cells. Therefore, it
seems to be necessary to emphasise the analysis of mdrl/P-
glycoprotein expression in primary leukaemias which were
cured by chemotherapy.
While the conditions of a complete transcriptional 'switch
off' of the mdrl gene as yet are unknown, the possible
intrinsic variability of mdrl gene expression levels in vivo in
response to chemotherapy, or as yet unknown dietary or
endogeneous factors has to be considered. Several recent
reports describe such rather short term quantitative altera-
tions. Thus, the mdrl gene expression was shown to be
inducible in rat liver by carcinogens and cocarcinogens (Fair-
child et al., 1987; Burt & Thorgeirsson, 1988), after gestation
in the endometrium of mice (Arceci et al., 1988), and by
differentiating agents in a colon carcinoma cell line (Mickley
et al., 1989). Moreover, we showed an increase of resistance
and mdrl mRNA levels within 72 h in a multidrug-resistant
CCRF-CEM subline (Gekeler et al., 1988), and more recently
in the parental cell line CCRF-CEM (Noller et al., 1991)
after treatment of the cells with actinomycin D. In all these
cases the mdrl gene was expressed prior to the treatment
albeit at distinctly lower levels. The inducibility of the mdrl
gene, however, might contribute to rather short term varia-
tions of the mdrl mRNA levels seen in tumour samples due,
for instance, to the time of sample collection and the applica-
tion of drugs. A more frequent gene expression analysis
might then answer the question, whether mdrl gene expres-
sion increases as a direct consequence of chemotherapy in
leukaemic blast cells not responding to chemotherapy but
showing low mdrl gene expression beforehand.
The analysis of topoisomerase I and II, histone 3.1, and
glutathione-S-transferase gene expression revealed no clear
relationship to the status of the leukaemias. However, it
might be useful for estimation of (i) target levels for many
antineoplastic drugs (topoisomerases), (ii) the proliferation
status of the cells (topoisomerase, histone 3.1), or (iii) the
sensitivity to alkylating agents or oxidative stress (gluta-
thione-S-transferase t).
In agreement with our data, a positive correlation was
found between mdrl and glutathione-S-transferase mRNA
levels in CLL but not the acute leukaemias by Holmes et al.
(1990b). A recent report on a variety of leukaemias, excep-
ting CLL though, suggests that cytotoxic drugs might inter-
fere with the transcription of the glutathione-S-transferase i
gene, because a sharp drop of expression was seen following
initiation of the chemotherapeutic treatment (McQuaid et al.,
1989). A more detailed gene expression analysis in respect to
treatment schedules of CLL seems to be useful to unravel
these interdependences. The meaning of the positive correla-
tions between the expression levels of the other genes in CLL
remains unclear, as well. Our data indicate a highly signi-
ficant link between mdrl gene expression and the histone 3.1
expression levels in this type of leukaemia, especially if the
treated CLL are examined separately. This points to an
association of mdrl gene expression with the proliferation
status of these tumour cells. Nevertheless, other factors pos-
sibly due to the peculiar drug treatment of CLL might be
responsible for this phenomenon.
Obviously, the activity of the DNA-synthesis machinery as
indicated by the histone 3.1 gene expression levels is cor-
related to topoisomerase I gene expression in general. This
correlation is significant at the P<0.001 level for the collec-
tion of the whole variety of samples examined by us. The
general link, however, between topoisomerase gene expres-
sion and the proliferation status of cells is not completely
understood. Our data do not indicate a relationship between
topoisomerase II gene expression and the status of DNA-
replication which does not exclude an interrelationship to the
cycling status of the cells, however. Hwong et al. (1990),
reported on the induction of topoisomerase II gene expres-
sion after phytohemagglutinin stimulation of human lym-
phocytes. In tumour cells, eventually, no difference was seen
between a resting and a proliferating state (Liu, 1989), and
similar topoisomerase II activities were found by Holden et
al. (1990) in normal or neoplastic tissues. The separate
analysis of several topoisomerase II subtypes which are
differently expressed and variously sensitive to drugs (Drake
et al., 1989; Holden et al., 1990) might help to unravel the as
yet unclear association of topoisomerase II expression to cell
proliferation, and the response of tumours to chemotherapy,
also.
Reports on atypical MDR-phenotypes of cell lines selected
in vitro showing either a reduced topoisomerase II expression
(Fernandes et al., 1990; DeJong et al., 1990), or the emer-
gence of an altered topoisomerase II enzyme (Pommier et al.,
1986) in these cells, suggest the occurrence of similar pheno-
menons in vivo. So far, only little information is available on
topoisomerase expression in cell samples from leukaemias.
Silber et al. (1989) measured topoisomerase II and
topoisomerase I levels by Western-immunoblotting in various
haematological malignancies including CLL which virtually
cannot be cured by chemotherapy at present. Their data
nicely correspond to ours, i.e. no significant topoisomerase II
gene expression was found in PBMC samples of CLL
patients or normal donors, while distinct topoisomerase I
expression was seen throughout. The authors suggest that a
resistance of leukaemias to topoisomerase II inhibitors like
the widely applicated drugs adriamycin and etoposide/VP-16
might be attributed to such low topoisomerase II levels.
Besides in the CLL samples, low or undetectable
topoisomerase II in combination with distinct or high
topoisomerase I mRNA levels were observed by us in other
leukaemias as well (AML 2, AML 5). A treatment of such
leukaemias showing no significant topoisomerase II gene exp-
ression with specific topoisomerase II inhibitors might not be
useful. It was shown recently that hypersensitivity of tissue
culture cells to the topoisomerase I inhibitor camptothecin is
linked to the overexpression of the topoisomerase I gene
(Madden & Champoux, 1992). Thus, if clinically applicable
topoisomerase I specific drugs will be available, their applica-
tion in those cases eventually could improve chemotherapy.
This might in general also be true for the numerous acute
leukaemias showing a very high topoisomerase I gene expres-
sion.
On the other hand, increased topoisomerase II levels were
paralled by increased sensitivities to intercalating drugs and516 V. GEKELER et al.
epipodophyllotoxins in various hamster cell lines, and the
human T-lymphoblastoid cell line CCRF-CEM (Sullivan et
al., 1987; Davies et al., 1988). Moreover, a correlation
between the clinical response of solid tumours towards adria-
mycin and the topoisomerase II expression levels were report-
ed by Kim et al. (1991). Hence, an intense application of
topoisomerase II inhibitors, at best drugs not transported by
the P-glycoprotein, might prove to be advantageous in leuka-
emias exhibiting strong topoisomerase II gene expression, as
monitored by us in numerous acute leukaemias.
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